context
stringlengths 21
24.6k
| category
stringclasses 2
values | entity
stringlengths 1
12
| entity_type
stringclasses 5
values | query
stringlengths 97
3.31k
| answer
stringlengths 12
168
|
|---|---|---|---|---|---|
As of December 31, 2024, the Company has entered into non-cancelable arrangements for subscription software services to make payments aggregating to $ 19.6 million over the next five years . | text | 19.6 | monetaryItemType | text: <entity> 19.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company has entered into non-cancelable arrangements for subscription software services to make payments aggregating to $ 19.6 million over the next five years . </context> | us-gaap:ContractualObligation |
The minimum commitments related to the Company's license arrangements aggregate to $ 14.6 million as of December 31, 2024 to be paid over the next 14 years. | text | 14.6 | monetaryItemType | text: <entity> 14.6 </entity> <entity type> monetaryItemType </entity type> <context> The minimum commitments related to the Company's license arrangements aggregate to $ 14.6 million as of December 31, 2024 to be paid over the next 14 years. </context> | us-gaap:ContractualObligation |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 12.6 | monetaryItemType | text: <entity> 12.6 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:OperatingLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 13.6 | monetaryItemType | text: <entity> 13.6 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:OperatingLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 13.1 | monetaryItemType | text: <entity> 13.1 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:OperatingLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:VariableLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:VariableLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:VariableLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:SubleaseIncome |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:SubleaseIncome |
Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. | text | 17.8 | monetaryItemType | text: <entity> 17.8 </entity> <entity type> monetaryItemType </entity type> <context> Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. </context> | us-gaap:OperatingLeasePayments |
Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. | text | 15.2 | monetaryItemType | text: <entity> 15.2 </entity> <entity type> monetaryItemType </entity type> <context> Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. </context> | us-gaap:OperatingLeasePayments |
Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. | text | 12.1 | monetaryItemType | text: <entity> 12.1 </entity> <entity type> monetaryItemType </entity type> <context> Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. </context> | us-gaap:OperatingLeasePayments |
For the year ended December 31, 2024, the Company incurred approximately $ 1.0 million costs associated with exit activities related to the lease expirations. | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, the Company incurred approximately $ 1.0 million costs associated with exit activities related to the lease expirations. </context> | us-gaap:GainLossOnTerminationOfLease |
On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. | text | 31 | monetaryItemType | text: <entity> 31 </entity> <entity type> monetaryItemType </entity type> <context> On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. </context> | us-gaap:LossContingencyDamagesSoughtValue |
On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. | text | 25 | monetaryItemType | text: <entity> 25 </entity> <entity type> monetaryItemType </entity type> <context> On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. </context> | us-gaap:GainLossRelatedToLitigationSettlement |
On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. </context> | us-gaap:PaymentsForRoyalties |
A hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString’s request conditioned upon NanoString posting a 2.3 million Euro security deposit. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> A hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString’s request conditioned upon NanoString posting a 2.3 million Euro security deposit. </context> | us-gaap:SecurityDeposit |
The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 1,200,000,000 shares of capital stock consisting of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock, and 100,000,000 shares of preferred stock. | text | 100000000 | sharesItemType | text: <entity> 100000000 </entity> <entity type> sharesItemType </entity type> <context> The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 1,200,000,000 shares of capital stock consisting of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock, and 100,000,000 shares of preferred stock. </context> | us-gaap:PreferredStockSharesAuthorized |
Following the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the Amended and Restated 2012 Stock Plan continue to be governed by their existing terms but no further awards may be granted under the Amended and Restated 2012 Stock Plan. As of December 31, 2024, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan which includes shares issuable upon the exercise of outstanding awards was 1,842,338 . | text | 1842338 | sharesItemType | text: <entity> 1842338 </entity> <entity type> sharesItemType </entity type> <context> Following the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the Amended and Restated 2012 Stock Plan continue to be governed by their existing terms but no further awards may be granted under the Amended and Restated 2012 Stock Plan. As of December 31, 2024, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan which includes shares issuable upon the exercise of outstanding awards was 1,842,338 . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The Omnibus Incentive Plan allows for the issuance of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”) or restricted shares. ISOs may be granted only to the Company’s employees (including officers and directors who are also considered employees). NSOs and restricted shares may be granted to the Company’s employees and service providers. As of December 31, 2024, the number of shares of Class A common stock available for issuance under the 2019 Omnibus Incentive Plan was 9,245,631 shares issuable in connection with outstanding awards and 19,637,882 shares reserved for issuance in connection with grants of future awards. | text | 19637882 | sharesItemType | text: <entity> 19637882 </entity> <entity type> sharesItemType </entity type> <context> The Omnibus Incentive Plan allows for the issuance of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”) or restricted shares. ISOs may be granted only to the Company’s employees (including officers and directors who are also considered employees). NSOs and restricted shares may be granted to the Company’s employees and service providers. As of December 31, 2024, the number of shares of Class A common stock available for issuance under the 2019 Omnibus Incentive Plan was 9,245,631 shares issuable in connection with outstanding awards and 19,637,882 shares reserved for issuance in connection with grants of future awards. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. | text | 11000000 | sharesItemType | text: <entity> 11000000 </entity> <entity type> sharesItemType </entity type> <context> The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. | text | 11000000 | sharesItemType | text: <entity> 11000000 </entity> <entity type> sharesItemType </entity type> <context> The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 33.67 | perShareItemType | text: <entity> 33.67 </entity> <entity type> perShareItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 32.95 | perShareItemType | text: <entity> 32.95 </entity> <entity type> perShareItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 12.3 | monetaryItemType | text: <entity> 12.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 78.0 | monetaryItemType | text: <entity> 78.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 89.5 | monetaryItemType | text: <entity> 89.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 19.5 | monetaryItemType | text: <entity> 19.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
As of December 31, 2024, the total unrecognized stock-based compensation related to RSUs was $ 194.4 million, which will be recognized over a weighted-average period of approximately three years . | text | 194.4 | monetaryItemType | text: <entity> 194.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the total unrecognized stock-based compensation related to RSUs was $ 194.4 million, which will be recognized over a weighted-average period of approximately three years . </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
In March 2024, the Company granted 219,168 performance stock units (“PSUs”) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company’s Compensation Committee of the Board of Directors as described below: | text | 219168 | sharesItemType | text: <entity> 219168 </entity> <entity type> sharesItemType </entity type> <context> In March 2024, the Company granted 219,168 performance stock units (“PSUs”) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company’s Compensation Committee of the Board of Directors as described below: </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
50 % of target PSUs earned will be based on the Company’s compound annual growth rate (CAGR) of the Company’s Revenue over a two-year performance period from January 1, 2024 to December 31, 2025. Holders may earn from 0 % to 175 % of the target amount of shares and earned PSUs will then be subject to service-based vesting; and | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> 50 % of target PSUs earned will be based on the Company’s compound annual growth rate (CAGR) of the Company’s Revenue over a two-year performance period from January 1, 2024 to December 31, 2025. Holders may earn from 0 % to 175 % of the target amount of shares and earned PSUs will then be subject to service-based vesting; and </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
50 % of target PSUs earned will be based on the relative Total Shareholder Return (TSR) of the Company’s common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2024 to December 31, 2026. Depending on the results relative to the TSR market condition, the holders may earn from 0 % to 200 % of the target amount of shares which will vest at the end of the performance period. | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> 50 % of target PSUs earned will be based on the relative Total Shareholder Return (TSR) of the Company’s common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2024 to December 31, 2026. Depending on the results relative to the TSR market condition, the holders may earn from 0 % to 200 % of the target amount of shares which will vest at the end of the performance period. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. | text | 37.43 | perShareItemType | text: <entity> 37.43 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. | text | 44.80 | perShareItemType | text: <entity> 44.80 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
In March 2023, the Company granted 172,842 performance restricted stock unit awards (“PSAs”) under the 2019 Plan to certain members of management, which are subject to the achievement of certain escalating stock price thresholds established by the Company's Compensation Committee of the Board of Directors. | text | 172842 | sharesItemType | text: <entity> 172842 </entity> <entity type> sharesItemType </entity type> <context> In March 2023, the Company granted 172,842 performance restricted stock unit awards (“PSAs”) under the 2019 Plan to certain members of management, which are subject to the achievement of certain escalating stock price thresholds established by the Company's Compensation Committee of the Board of Directors. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. | text | 43.13 | perShareItemType | text: <entity> 43.13 </entity> <entity type> perShareItemType </entity type> <context> The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. | text | 5.1 | monetaryItemType | text: <entity> 5.1 </entity> <entity type> monetaryItemType </entity type> <context> The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
In September 2022, the Company granted 709,025 PSAs including RSUs and a performance stock option under the 2019 Plan to certain members of management, which are subject to the achievement of certain stock price thresholds established by the Company’s Compensation Committee of the Board of Directors. | text | 709025 | sharesItemType | text: <entity> 709025 </entity> <entity type> sharesItemType </entity type> <context> In September 2022, the Company granted 709,025 PSAs including RSUs and a performance stock option under the 2019 Plan to certain members of management, which are subject to the achievement of certain stock price thresholds established by the Company’s Compensation Committee of the Board of Directors. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 22.55 | perShareItemType | text: <entity> 22.55 </entity> <entity type> perShareItemType </entity type> <context> The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 2.4 | monetaryItemType | text: <entity> 2.4 </entity> <entity type> monetaryItemType </entity type> <context> The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> The PSAs consist of three separate tranches and the vesting of each tranche is subject to the Class A common stock closing price being maintained at or above the predetermined share price goals of $ 60 , $ 80 and $ 105 for each tranche, respectively, for a period of 20 consecutive trading days. The share price goals can be met any time prior to the fourth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price goals, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 22.55 . Stock-based compensation expense recognized for these market-based awards was approximately $ 2.4 million, $ 10.0 million and $ 3.3 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
In July 2019, the Company’s board of directors adopted the 10x Genomics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders. The ESPP went into effect on September 11, 2019. Subject to any limitations contained therein, the ESPP allows eligible employees to contribute, through payroll deductions, up to 15 % of their eligible compensation to purchase the Company’s Class A common stock at a discounted price per share. The ESPP generally provides for consecutive 6-month offering periods. | text | 15 | percentItemType | text: <entity> 15 </entity> <entity type> percentItemType </entity type> <context> In July 2019, the Company’s board of directors adopted the 10x Genomics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders. The ESPP went into effect on September 11, 2019. Subject to any limitations contained therein, the ESPP allows eligible employees to contribute, through payroll deductions, up to 15 % of their eligible compensation to purchase the Company’s Class A common stock at a discounted price per share. The ESPP generally provides for consecutive 6-month offering periods. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate |
During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. | text | 385967 | sharesItemType | text: <entity> 385967 </entity> <entity type> sharesItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. | text | 217537 | sharesItemType | text: <entity> 217537 </entity> <entity type> sharesItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. | text | 151028 | sharesItemType | text: <entity> 151028 </entity> <entity type> sharesItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. | text | 3686671 | sharesItemType | text: <entity> 3686671 </entity> <entity type> sharesItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. | text | 2705096 | sharesItemType | text: <entity> 2705096 </entity> <entity type> sharesItemType </entity type> <context> During the years ended December 31, 2024, 2023 and 2022, 385,967 , 217,537 , and 151,028 shares of Class A common stock, respectively, were issued under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 3,686,671 , which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1 % described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. As of December 31, 2024, there were 2,705,096 shares available for issuance under the ESPP. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
For the years ended December 31, 2024, 2023, and 2022 the weighted average grant date fair values of options granted under the ESPP, using the Black-Scholes option pricing model, were $ 6.42 , $ 16.91 , and $ 33.74 respectively. | text | 6.42 | perShareItemType | text: <entity> 6.42 </entity> <entity type> perShareItemType </entity type> <context> For the years ended December 31, 2024, 2023, and 2022 the weighted average grant date fair values of options granted under the ESPP, using the Black-Scholes option pricing model, were $ 6.42 , $ 16.91 , and $ 33.74 respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
For the years ended December 31, 2024, 2023, and 2022 the weighted average grant date fair values of options granted under the ESPP, using the Black-Scholes option pricing model, were $ 6.42 , $ 16.91 , and $ 33.74 respectively. | text | 16.91 | perShareItemType | text: <entity> 16.91 </entity> <entity type> perShareItemType </entity type> <context> For the years ended December 31, 2024, 2023, and 2022 the weighted average grant date fair values of options granted under the ESPP, using the Black-Scholes option pricing model, were $ 6.42 , $ 16.91 , and $ 33.74 respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
For the years ended December 31, 2024, 2023, and 2022 the weighted average grant date fair values of options granted under the ESPP, using the Black-Scholes option pricing model, were $ 6.42 , $ 16.91 , and $ 33.74 respectively. | text | 33.74 | perShareItemType | text: <entity> 33.74 </entity> <entity type> perShareItemType </entity type> <context> For the years ended December 31, 2024, 2023, and 2022 the weighted average grant date fair values of options granted under the ESPP, using the Black-Scholes option pricing model, were $ 6.42 , $ 16.91 , and $ 33.74 respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of December 31, 2024, the total unrecognized stock-based compensation related to the ESPP was $ 1.5 million, which will be recognized over a weighted-average period of approximately 0.4 years. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the total unrecognized stock-based compensation related to the ESPP was $ 1.5 million, which will be recognized over a weighted-average period of approximately 0.4 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. </context> | us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage |
The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. | text | 3 | percentItemType | text: <entity> 3 </entity> <entity type> percentItemType </entity type> <context> The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. </context> | us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch |
The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. | text | two thousand | monetaryItemType | text: <entity> two thousand </entity> <entity type> monetaryItemType </entity type> <context> The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. </context> | us-gaap:DefinedBenefitPlanContributionsByEmployer |
The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. </context> | us-gaap:DefinedBenefitPlanContributionsByEmployer |
The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. </context> | us-gaap:DefinedBenefitPlanContributionsByEmployer |
The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company matches 100 % of the first 3 % of the employee's eligible compensation, up to a maximum of two thousand dollars annually per employee. The Company contributed $ 1.9 million, $ 1.8 million, and $ 2.0 million for the years ended December 31, 2024, 2023, and 2022 respectively. </context> | us-gaap:DefinedBenefitPlanContributionsByEmployer |
Omega has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes and is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega's assets are owned directly or indirectly by, and all of Omega's operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with subsidiaries, “Omega OP”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the partnership agreement governing Omega OP. As of December 31, 2024, Parent owned approximately 97 % of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 3 % of the outstanding Omega OP Units. | text | 97 | percentItemType | text: <entity> 97 </entity> <entity type> percentItemType </entity type> <context> Omega has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes and is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega's assets are owned directly or indirectly by, and all of Omega's operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with subsidiaries, “Omega OP”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the partnership agreement governing Omega OP. As of December 31, 2024, Parent owned approximately 97 % of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 3 % of the outstanding Omega OP Units. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest |
Omega has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes and is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega's assets are owned directly or indirectly by, and all of Omega's operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with subsidiaries, “Omega OP”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the partnership agreement governing Omega OP. As of December 31, 2024, Parent owned approximately 97 % of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 3 % of the outstanding Omega OP Units. | text | 3 | percentItemType | text: <entity> 3 </entity> <entity type> percentItemType </entity type> <context> Omega has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes and is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega's assets are owned directly or indirectly by, and all of Omega's operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with subsidiaries, “Omega OP”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the partnership agreement governing Omega OP. As of December 31, 2024, Parent owned approximately 97 % of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 3 % of the outstanding Omega OP Units. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest |
Real estate properties are carried at initial recorded value less accumulated depreciation. The costs of significant improvements, renovations and replacements, including interest are capitalized. Our interest expense reflected in the Consolidated Statements of Operations has been reduced by the amounts capitalized. For the years ended December 31, 2024, 2023 and 2022, we capitalized $ 7.3 million, $ 4.3 million and $ 3.2 million, respectively, of interest to our projects under development. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are expensed as they are incurred. | text | 7.3 | monetaryItemType | text: <entity> 7.3 </entity> <entity type> monetaryItemType </entity type> <context> Real estate properties are carried at initial recorded value less accumulated depreciation. The costs of significant improvements, renovations and replacements, including interest are capitalized. Our interest expense reflected in the Consolidated Statements of Operations has been reduced by the amounts capitalized. For the years ended December 31, 2024, 2023 and 2022, we capitalized $ 7.3 million, $ 4.3 million and $ 3.2 million, respectively, of interest to our projects under development. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are expensed as they are incurred. </context> | us-gaap:RealEstateInventoryCapitalizedInterestCosts |
Real estate properties are carried at initial recorded value less accumulated depreciation. The costs of significant improvements, renovations and replacements, including interest are capitalized. Our interest expense reflected in the Consolidated Statements of Operations has been reduced by the amounts capitalized. For the years ended December 31, 2024, 2023 and 2022, we capitalized $ 7.3 million, $ 4.3 million and $ 3.2 million, respectively, of interest to our projects under development. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are expensed as they are incurred. | text | 4.3 | monetaryItemType | text: <entity> 4.3 </entity> <entity type> monetaryItemType </entity type> <context> Real estate properties are carried at initial recorded value less accumulated depreciation. The costs of significant improvements, renovations and replacements, including interest are capitalized. Our interest expense reflected in the Consolidated Statements of Operations has been reduced by the amounts capitalized. For the years ended December 31, 2024, 2023 and 2022, we capitalized $ 7.3 million, $ 4.3 million and $ 3.2 million, respectively, of interest to our projects under development. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are expensed as they are incurred. </context> | us-gaap:RealEstateInventoryCapitalizedInterestCosts |
Real estate properties are carried at initial recorded value less accumulated depreciation. The costs of significant improvements, renovations and replacements, including interest are capitalized. Our interest expense reflected in the Consolidated Statements of Operations has been reduced by the amounts capitalized. For the years ended December 31, 2024, 2023 and 2022, we capitalized $ 7.3 million, $ 4.3 million and $ 3.2 million, respectively, of interest to our projects under development. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are expensed as they are incurred. | text | 3.2 | monetaryItemType | text: <entity> 3.2 </entity> <entity type> monetaryItemType </entity type> <context> Real estate properties are carried at initial recorded value less accumulated depreciation. The costs of significant improvements, renovations and replacements, including interest are capitalized. Our interest expense reflected in the Consolidated Statements of Operations has been reduced by the amounts capitalized. For the years ended December 31, 2024, 2023 and 2022, we capitalized $ 7.3 million, $ 4.3 million and $ 3.2 million, respectively, of interest to our projects under development. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are expensed as they are incurred. </context> | us-gaap:RealEstateInventoryCapitalizedInterestCosts |
We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. | text | 15.5 | monetaryItemType | text: <entity> 15.5 </entity> <entity type> monetaryItemType </entity type> <context> We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. </context> | us-gaap:SecurityDeposit |
We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. </context> | us-gaap:SecurityDeposit |
We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. | text | 52.7 | monetaryItemType | text: <entity> 52.7 </entity> <entity type> monetaryItemType </entity type> <context> We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. </context> | us-gaap:SecurityDeposit |
We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. | text | 36.0 | monetaryItemType | text: <entity> 36.0 </entity> <entity type> monetaryItemType </entity type> <context> We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. </context> | us-gaap:SecurityDeposit |
We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. | text | 29.1 | monetaryItemType | text: <entity> 29.1 </entity> <entity type> monetaryItemType </entity type> <context> We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. </context> | us-gaap:SecurityDeposit |
We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. | text | 27.1 | monetaryItemType | text: <entity> 27.1 </entity> <entity type> monetaryItemType </entity type> <context> We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2024 and 2023, we held $ 15.5 million and $ 1.9 million, respectively, in liquidity and other deposits and $ 52.7 million and $ 36.0 million, respectively, in security deposits. We also had the ability to draw on $ 29.1 million and $ 27.1 million of letters of credit at December 31, 2024 and 2023, respectively. </context> | us-gaap:SecurityDeposit |
External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. Any difference between fair value and stated value of debt, assumed in an assets acquisition or business combination, is recorded as a discount or premium and amortized over the remaining term of the loan. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Net amortization of deferred financing costs and premiums or discounts totaled $ 10.4 million, $ 13.7 million and $ 12.9 million for the years ended December 31, 2024, 2023 and 2022, respectively, and are recorded in interest expense on our Consolidated Statements of Operations. | text | 10.4 | monetaryItemType | text: <entity> 10.4 </entity> <entity type> monetaryItemType </entity type> <context> External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. Any difference between fair value and stated value of debt, assumed in an assets acquisition or business combination, is recorded as a discount or premium and amortized over the remaining term of the loan. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Net amortization of deferred financing costs and premiums or discounts totaled $ 10.4 million, $ 13.7 million and $ 12.9 million for the years ended December 31, 2024, 2023 and 2022, respectively, and are recorded in interest expense on our Consolidated Statements of Operations. </context> | us-gaap:AmortizationOfFinancingCosts |
External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. Any difference between fair value and stated value of debt, assumed in an assets acquisition or business combination, is recorded as a discount or premium and amortized over the remaining term of the loan. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Net amortization of deferred financing costs and premiums or discounts totaled $ 10.4 million, $ 13.7 million and $ 12.9 million for the years ended December 31, 2024, 2023 and 2022, respectively, and are recorded in interest expense on our Consolidated Statements of Operations. | text | 13.7 | monetaryItemType | text: <entity> 13.7 </entity> <entity type> monetaryItemType </entity type> <context> External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. Any difference between fair value and stated value of debt, assumed in an assets acquisition or business combination, is recorded as a discount or premium and amortized over the remaining term of the loan. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Net amortization of deferred financing costs and premiums or discounts totaled $ 10.4 million, $ 13.7 million and $ 12.9 million for the years ended December 31, 2024, 2023 and 2022, respectively, and are recorded in interest expense on our Consolidated Statements of Operations. </context> | us-gaap:AmortizationOfFinancingCosts |
External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. Any difference between fair value and stated value of debt, assumed in an assets acquisition or business combination, is recorded as a discount or premium and amortized over the remaining term of the loan. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Net amortization of deferred financing costs and premiums or discounts totaled $ 10.4 million, $ 13.7 million and $ 12.9 million for the years ended December 31, 2024, 2023 and 2022, respectively, and are recorded in interest expense on our Consolidated Statements of Operations. | text | 12.9 | monetaryItemType | text: <entity> 12.9 </entity> <entity type> monetaryItemType </entity type> <context> External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. Any difference between fair value and stated value of debt, assumed in an assets acquisition or business combination, is recorded as a discount or premium and amortized over the remaining term of the loan. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Net amortization of deferred financing costs and premiums or discounts totaled $ 10.4 million, $ 13.7 million and $ 12.9 million for the years ended December 31, 2024, 2023 and 2022, respectively, and are recorded in interest expense on our Consolidated Statements of Operations. </context> | us-gaap:AmortizationOfFinancingCosts |
The noncontrolling interest for Omega primarily represents the outstanding Omega OP Units held by outside investors. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $ 0.10 per share (“Omega Common Stock”), subject to Omega’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one -for-one basis, subject to adjustment as set forth in Omega OP’s partnership agreement. As of December 31, 2024, Omega owns approximately 97 % of the issued and outstanding Omega OP Units, and investors own approximately 3 % of the outstanding Omega OP Units. | text | 0.10 | perShareItemType | text: <entity> 0.10 </entity> <entity type> perShareItemType </entity type> <context> The noncontrolling interest for Omega primarily represents the outstanding Omega OP Units held by outside investors. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $ 0.10 per share (“Omega Common Stock”), subject to Omega’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one -for-one basis, subject to adjustment as set forth in Omega OP’s partnership agreement. As of December 31, 2024, Omega owns approximately 97 % of the issued and outstanding Omega OP Units, and investors own approximately 3 % of the outstanding Omega OP Units. </context> | us-gaap:CommonStockParOrStatedValuePerShare |
The noncontrolling interest for Omega primarily represents the outstanding Omega OP Units held by outside investors. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $ 0.10 per share (“Omega Common Stock”), subject to Omega’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one -for-one basis, subject to adjustment as set forth in Omega OP’s partnership agreement. As of December 31, 2024, Omega owns approximately 97 % of the issued and outstanding Omega OP Units, and investors own approximately 3 % of the outstanding Omega OP Units. | text | 97 | percentItemType | text: <entity> 97 </entity> <entity type> percentItemType </entity type> <context> The noncontrolling interest for Omega primarily represents the outstanding Omega OP Units held by outside investors. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $ 0.10 per share (“Omega Common Stock”), subject to Omega’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one -for-one basis, subject to adjustment as set forth in Omega OP’s partnership agreement. As of December 31, 2024, Omega owns approximately 97 % of the issued and outstanding Omega OP Units, and investors own approximately 3 % of the outstanding Omega OP Units. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest |
The noncontrolling interest for Omega primarily represents the outstanding Omega OP Units held by outside investors. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $ 0.10 per share (“Omega Common Stock”), subject to Omega’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one -for-one basis, subject to adjustment as set forth in Omega OP’s partnership agreement. As of December 31, 2024, Omega owns approximately 97 % of the issued and outstanding Omega OP Units, and investors own approximately 3 % of the outstanding Omega OP Units. | text | 3 | percentItemType | text: <entity> 3 </entity> <entity type> percentItemType </entity type> <context> The noncontrolling interest for Omega primarily represents the outstanding Omega OP Units held by outside investors. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $ 0.10 per share (“Omega Common Stock”), subject to Omega’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one -for-one basis, subject to adjustment as set forth in Omega OP’s partnership agreement. As of December 31, 2024, Omega owns approximately 97 % of the issued and outstanding Omega OP Units, and investors own approximately 3 % of the outstanding Omega OP Units. </context> | us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest |
The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). Total revenues from our consolidated U.K. operating subsidiaries were $ 93.6 million, $ 56.8 million and $ 47.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our consolidated U.K. operating subsidiaries held long-lived assets of $ 1.1 billion and $ 539.6 million as of December 31, 2024 and 2023, respectively. | text | 93.6 | monetaryItemType | text: <entity> 93.6 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). Total revenues from our consolidated U.K. operating subsidiaries were $ 93.6 million, $ 56.8 million and $ 47.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our consolidated U.K. operating subsidiaries held long-lived assets of $ 1.1 billion and $ 539.6 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:Revenues |
The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). Total revenues from our consolidated U.K. operating subsidiaries were $ 93.6 million, $ 56.8 million and $ 47.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our consolidated U.K. operating subsidiaries held long-lived assets of $ 1.1 billion and $ 539.6 million as of December 31, 2024 and 2023, respectively. | text | 56.8 | monetaryItemType | text: <entity> 56.8 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). Total revenues from our consolidated U.K. operating subsidiaries were $ 93.6 million, $ 56.8 million and $ 47.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our consolidated U.K. operating subsidiaries held long-lived assets of $ 1.1 billion and $ 539.6 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:Revenues |
The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). Total revenues from our consolidated U.K. operating subsidiaries were $ 93.6 million, $ 56.8 million and $ 47.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our consolidated U.K. operating subsidiaries held long-lived assets of $ 1.1 billion and $ 539.6 million as of December 31, 2024 and 2023, respectively. | text | 47.7 | monetaryItemType | text: <entity> 47.7 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). Total revenues from our consolidated U.K. operating subsidiaries were $ 93.6 million, $ 56.8 million and $ 47.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. Our consolidated U.K. operating subsidiaries held long-lived assets of $ 1.1 billion and $ 539.6 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:Revenues |
Certain amounts in the prior year period have been reclassified to conform to the current period presentation. Income from direct financing leases, which was previously reported separately on our Consolidated Statements of Operations, is now included in rental income for all periods presented. In addition, we previously reported assets held for sale of $ 93.7 million on the Consolidated Balance Sheet as of December 31, 2023. In the first quarter of 2024 and the fourth quarter of 2024, it was determined that $ 12.2 million and $ 14.4 million, respectively, of these assets no longer qualified as held for sale and were reclassified to assets held for use within the applicable line items in real estate assets – net on the Consolidated Balance Sheet as of December 31, 2023. Of the $ 26.6 million reclassified net of $ 11.1 million of accumulated depreciation, $ 30.9 million relates to buildings, $ 3.4 million relates to land and $ 3.4 million relates to furniture and equipment. | text | 93.7 | monetaryItemType | text: <entity> 93.7 </entity> <entity type> monetaryItemType </entity type> <context> Certain amounts in the prior year period have been reclassified to conform to the current period presentation. Income from direct financing leases, which was previously reported separately on our Consolidated Statements of Operations, is now included in rental income for all periods presented. In addition, we previously reported assets held for sale of $ 93.7 million on the Consolidated Balance Sheet as of December 31, 2023. In the first quarter of 2024 and the fourth quarter of 2024, it was determined that $ 12.2 million and $ 14.4 million, respectively, of these assets no longer qualified as held for sale and were reclassified to assets held for use within the applicable line items in real estate assets – net on the Consolidated Balance Sheet as of December 31, 2023. Of the $ 26.6 million reclassified net of $ 11.1 million of accumulated depreciation, $ 30.9 million relates to buildings, $ 3.4 million relates to land and $ 3.4 million relates to furniture and equipment. </context> | us-gaap:RealEstateHeldforsale |
On March 12, 2020, the FASB issued ASU 2020-04, which contains optional practical expedients for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). The guidance may be elected over time until December 31, 2022, as reference rate reform activities occur. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the practical expedients under ASU 2020-04 to December 31, 2024. The Company had several derivative instruments that referenced LIBOR which were terminated during the second quarter of 2023 (see Note 15 – Derivatives and Hedging). The Company also had a $ 1.45 billion senior unsecured multicurrency revolving credit facility and a $ 50.0 million senior unsecured term loan facility (see Note 14 – Borrowing Activities and Arrangements) that referenced LIBOR. During the second quarter of 2023, the Company amended its $ 1.45 billion senior unsecured multicurrency revolving credit facility and $ 50.0 million senior unsecured term loan facility to adjust the interest on each loan from a LIBOR based interest rate to a Secured Overnight Financing Rate (“SOFR”) based interest rate. For both loans we have elected to apply the optional expedient pursuant to Topic 848. As such we will account for the amendments as if the modifications were not substantial and thus a continuation of the existing contract resulting in no change to the current loan carrying values or the related deferred financing costs. | text | 1.45 | monetaryItemType | text: <entity> 1.45 </entity> <entity type> monetaryItemType </entity type> <context> On March 12, 2020, the FASB issued ASU 2020-04, which contains optional practical expedients for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). The guidance may be elected over time until December 31, 2022, as reference rate reform activities occur. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the practical expedients under ASU 2020-04 to December 31, 2024. The Company had several derivative instruments that referenced LIBOR which were terminated during the second quarter of 2023 (see Note 15 – Derivatives and Hedging). The Company also had a $ 1.45 billion senior unsecured multicurrency revolving credit facility and a $ 50.0 million senior unsecured term loan facility (see Note 14 – Borrowing Activities and Arrangements) that referenced LIBOR. During the second quarter of 2023, the Company amended its $ 1.45 billion senior unsecured multicurrency revolving credit facility and $ 50.0 million senior unsecured term loan facility to adjust the interest on each loan from a LIBOR based interest rate to a Secured Overnight Financing Rate (“SOFR”) based interest rate. For both loans we have elected to apply the optional expedient pursuant to Topic 848. As such we will account for the amendments as if the modifications were not substantial and thus a continuation of the existing contract resulting in no change to the current loan carrying values or the related deferred financing costs. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On March 12, 2020, the FASB issued ASU 2020-04, which contains optional practical expedients for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). The guidance may be elected over time until December 31, 2022, as reference rate reform activities occur. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the practical expedients under ASU 2020-04 to December 31, 2024. The Company had several derivative instruments that referenced LIBOR which were terminated during the second quarter of 2023 (see Note 15 – Derivatives and Hedging). The Company also had a $ 1.45 billion senior unsecured multicurrency revolving credit facility and a $ 50.0 million senior unsecured term loan facility (see Note 14 – Borrowing Activities and Arrangements) that referenced LIBOR. During the second quarter of 2023, the Company amended its $ 1.45 billion senior unsecured multicurrency revolving credit facility and $ 50.0 million senior unsecured term loan facility to adjust the interest on each loan from a LIBOR based interest rate to a Secured Overnight Financing Rate (“SOFR”) based interest rate. For both loans we have elected to apply the optional expedient pursuant to Topic 848. As such we will account for the amendments as if the modifications were not substantial and thus a continuation of the existing contract resulting in no change to the current loan carrying values or the related deferred financing costs. | text | 50.0 | monetaryItemType | text: <entity> 50.0 </entity> <entity type> monetaryItemType </entity type> <context> On March 12, 2020, the FASB issued ASU 2020-04, which contains optional practical expedients for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). The guidance may be elected over time until December 31, 2022, as reference rate reform activities occur. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the practical expedients under ASU 2020-04 to December 31, 2024. The Company had several derivative instruments that referenced LIBOR which were terminated during the second quarter of 2023 (see Note 15 – Derivatives and Hedging). The Company also had a $ 1.45 billion senior unsecured multicurrency revolving credit facility and a $ 50.0 million senior unsecured term loan facility (see Note 14 – Borrowing Activities and Arrangements) that referenced LIBOR. During the second quarter of 2023, the Company amended its $ 1.45 billion senior unsecured multicurrency revolving credit facility and $ 50.0 million senior unsecured term loan facility to adjust the interest on each loan from a LIBOR based interest rate to a Secured Overnight Financing Rate (“SOFR”) based interest rate. For both loans we have elected to apply the optional expedient pursuant to Topic 848. As such we will account for the amendments as if the modifications were not substantial and thus a continuation of the existing contract resulting in no change to the current loan carrying values or the related deferred financing costs. </context> | us-gaap:OtherLoansPayable |
As of December 31, 2023, we held a 49 % interest in an unconsolidated real estate joint venture owning 63 facilities in the U.K. (the “Cindat Joint Venture”) accounted for using the equity method of accounting. As of December 31, 2023, our equity interest was $ 97.6 million. The 63 facilities are subject to leases with two operators that have contractual rent of $ 43.6 million per annum with minimum escalators between 1.0 % to 2.0 % that can escalate further based on certain inflationary measures. | text | 49 | percentItemType | text: <entity> 49 </entity> <entity type> percentItemType </entity type> <context> As of December 31, 2023, we held a 49 % interest in an unconsolidated real estate joint venture owning 63 facilities in the U.K. (the “Cindat Joint Venture”) accounted for using the equity method of accounting. As of December 31, 2023, our equity interest was $ 97.6 million. The 63 facilities are subject to leases with two operators that have contractual rent of $ 43.6 million per annum with minimum escalators between 1.0 % to 2.0 % that can escalate further based on certain inflationary measures. </context> | us-gaap:EquityMethodInvestmentOwnershipPercentage |
As of December 31, 2023, we held a 49 % interest in an unconsolidated real estate joint venture owning 63 facilities in the U.K. (the “Cindat Joint Venture”) accounted for using the equity method of accounting. As of December 31, 2023, our equity interest was $ 97.6 million. The 63 facilities are subject to leases with two operators that have contractual rent of $ 43.6 million per annum with minimum escalators between 1.0 % to 2.0 % that can escalate further based on certain inflationary measures. | text | 63 | integerItemType | text: <entity> 63 </entity> <entity type> integerItemType </entity type> <context> As of December 31, 2023, we held a 49 % interest in an unconsolidated real estate joint venture owning 63 facilities in the U.K. (the “Cindat Joint Venture”) accounted for using the equity method of accounting. As of December 31, 2023, our equity interest was $ 97.6 million. The 63 facilities are subject to leases with two operators that have contractual rent of $ 43.6 million per annum with minimum escalators between 1.0 % to 2.0 % that can escalate further based on certain inflationary measures. </context> | us-gaap:NumberOfRealEstateProperties |
As of December 31, 2023, we held a 49 % interest in an unconsolidated real estate joint venture owning 63 facilities in the U.K. (the “Cindat Joint Venture”) accounted for using the equity method of accounting. As of December 31, 2023, our equity interest was $ 97.6 million. The 63 facilities are subject to leases with two operators that have contractual rent of $ 43.6 million per annum with minimum escalators between 1.0 % to 2.0 % that can escalate further based on certain inflationary measures. | text | 97.6 | monetaryItemType | text: <entity> 97.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we held a 49 % interest in an unconsolidated real estate joint venture owning 63 facilities in the U.K. (the “Cindat Joint Venture”) accounted for using the equity method of accounting. As of December 31, 2023, our equity interest was $ 97.6 million. The 63 facilities are subject to leases with two operators that have contractual rent of $ 43.6 million per annum with minimum escalators between 1.0 % to 2.0 % that can escalate further based on certain inflationary measures. </context> | us-gaap:EquityMethodInvestments |
In July 2024, we acquired the remaining 51 % interest in the Cindat Joint Venture for total consideration of $ 364.9 million inclusive of: (i) $ 98.9 million of cash consideration including direct transaction costs, (ii) the assumption of a £ 188.6 million mortgage loan (the “2026 Mortgage Loan”) with an estimated fair value of $ 264.0 million and (iii) deferred contingent consideration of $ 2.0 million that was paid in December 2024. The fair market value of the mortgage debt assumed was determined by discounting the remaining contractual cash flows using a current market rate of interest of comparable debt instruments. | text | 98.9 | monetaryItemType | text: <entity> 98.9 </entity> <entity type> monetaryItemType </entity type> <context> In July 2024, we acquired the remaining 51 % interest in the Cindat Joint Venture for total consideration of $ 364.9 million inclusive of: (i) $ 98.9 million of cash consideration including direct transaction costs, (ii) the assumption of a £ 188.6 million mortgage loan (the “2026 Mortgage Loan”) with an estimated fair value of $ 264.0 million and (iii) deferred contingent consideration of $ 2.0 million that was paid in December 2024. The fair market value of the mortgage debt assumed was determined by discounting the remaining contractual cash flows using a current market rate of interest of comparable debt instruments. </context> | us-gaap:PaymentsToAcquireInterestInJointVenture |
In July 2024, we acquired the remaining 51 % interest in the Cindat Joint Venture for total consideration of $ 364.9 million inclusive of: (i) $ 98.9 million of cash consideration including direct transaction costs, (ii) the assumption of a £ 188.6 million mortgage loan (the “2026 Mortgage Loan”) with an estimated fair value of $ 264.0 million and (iii) deferred contingent consideration of $ 2.0 million that was paid in December 2024. The fair market value of the mortgage debt assumed was determined by discounting the remaining contractual cash flows using a current market rate of interest of comparable debt instruments. | text | 264.0 | monetaryItemType | text: <entity> 264.0 </entity> <entity type> monetaryItemType </entity type> <context> In July 2024, we acquired the remaining 51 % interest in the Cindat Joint Venture for total consideration of $ 364.9 million inclusive of: (i) $ 98.9 million of cash consideration including direct transaction costs, (ii) the assumption of a £ 188.6 million mortgage loan (the “2026 Mortgage Loan”) with an estimated fair value of $ 264.0 million and (iii) deferred contingent consideration of $ 2.0 million that was paid in December 2024. The fair market value of the mortgage debt assumed was determined by discounting the remaining contractual cash flows using a current market rate of interest of comparable debt instruments. </context> | us-gaap:LoansAssumed1 |
In July 2024, we acquired the remaining 51 % interest in the Cindat Joint Venture for total consideration of $ 364.9 million inclusive of: (i) $ 98.9 million of cash consideration including direct transaction costs, (ii) the assumption of a £ 188.6 million mortgage loan (the “2026 Mortgage Loan”) with an estimated fair value of $ 264.0 million and (iii) deferred contingent consideration of $ 2.0 million that was paid in December 2024. The fair market value of the mortgage debt assumed was determined by discounting the remaining contractual cash flows using a current market rate of interest of comparable debt instruments. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> In July 2024, we acquired the remaining 51 % interest in the Cindat Joint Venture for total consideration of $ 364.9 million inclusive of: (i) $ 98.9 million of cash consideration including direct transaction costs, (ii) the assumption of a £ 188.6 million mortgage loan (the “2026 Mortgage Loan”) with an estimated fair value of $ 264.0 million and (iii) deferred contingent consideration of $ 2.0 million that was paid in December 2024. The fair market value of the mortgage debt assumed was determined by discounting the remaining contractual cash flows using a current market rate of interest of comparable debt instruments. </context> | us-gaap:AssetAcquisitionContingentConsiderationLiability |
During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. | text | 0.8 | monetaryItemType | text: <entity> 0.8 </entity> <entity type> monetaryItemType </entity type> <context> During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. </context> | us-gaap:PaymentsToAcquireCommercialRealEstate |
During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. | text | 15.2 | monetaryItemType | text: <entity> 15.2 </entity> <entity type> monetaryItemType </entity type> <context> During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. </context> | us-gaap:OtherCommitment |
During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. </context> | us-gaap:DevelopmentInProcess |
During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. | text | 2.4 | monetaryItemType | text: <entity> 2.4 </entity> <entity type> monetaryItemType </entity type> <context> During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. As of December 31, 2024 and 2023, $ 2.5 million and $ 2.4 million, respectively, was included in construction in progress related to this development project. </context> | us-gaap:DevelopmentInProcess |
During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. | text | 21 | integerItemType | text: <entity> 21 </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. | text | 14 | integerItemType | text: <entity> 14 </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. | text | six | integerItemType | text: <entity> six </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. </context> | us-gaap:NumberOfRealEstateProperties |
During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. | text | 95.0 | monetaryItemType | text: <entity> 95.0 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. </context> | us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment |
During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. | text | 13.2 | monetaryItemType | text: <entity> 13.2 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. </context> | us-gaap:GainLossOnDispositionOfAssets |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.